Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Crossject SA

Market Cap 103M 118M 94.98M 88.65M 166M 11.1B 168M 1.13B 439M 5.46B 441M 432M 18.97B P/E 2026 *
4.6x
P/E 2027 * 3.63x
Enterprise Value 84.78M 97.03M 78.42M 73.2M 137M 9.17B 138M 932M 363M 4.51B 364M 356M 15.66B EV / Sales 2026 *
1.39x
EV / Sales 2027 * 1.32x
Free-Float
89.86%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 08/08/2001
Director of Finance/CFO - 25/03/2026
Corporate Officer/Principal - 20/08/2024
Director TitleAgeSince
Chairman 67 26/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-2.97%-17.07%-70.77% 84.2M
-2.69%-13.72%+68.74%+1.74% 75.42M
Average -1.19%-11.11%+25.83%-34.52% 79.81M
Weighted average by Cap. -1.11%-11.04%+23.47%-36.51%

Financials

2026 *2027 *
Net sales 60.8M 69.58M 56.24M 52.49M 98.54M 6.58B 99.26M 668M 260M 3.23B 261M 256M 11.23B 42.3M 48.41M 39.13M 36.52M 68.56M 4.57B 69.06M 465M 181M 2.25B 182M 178M 7.81B
Net income 28.3M 32.39M 26.18M 24.43M 45.87M 3.06B 46.2M 311M 121M 1.5B 122M 119M 5.23B 7.75M 8.87M 7.17M 6.69M 12.56M 838M 12.65M 85.19M 33.15M 412M 33.3M 32.58M 1.43B
Net Debt -17.9M -20.49M -16.56M -15.45M -29.01M -1.94B -29.22M -197M -76.56M -952M -76.91M -75.24M -3.31B -47M -53.79M -43.47M -40.58M -76.18M -5.08B -76.73M -517M -201M -2.5B -202M -198M -8.68B
Logo Crossject SA
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!